InMed Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for InMed Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InMed Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 5 | -7 | -7 | -7 | N/A |
| 6/30/2024 | 5 | -8 | -7 | -7 | N/A |
| 3/31/2024 | 6 | -6 | -7 | -7 | N/A |
| 12/31/2023 | 5 | -6 | -7 | -6 | N/A |
| 9/30/2023 | 5 | -7 | -7 | -7 | N/A |
| 6/30/2023 | 4 | -8 | -7 | -7 | N/A |
| 3/31/2023 | 2 | -15 | -11 | -11 | N/A |
| 12/31/2022 | 2 | -17 | -14 | -14 | N/A |
| 9/30/2022 | 1 | -19 | -15 | -15 | N/A |
| 6/30/2022 | 1 | -19 | -16 | -16 | N/A |
| 3/31/2022 | 1 | -14 | -14 | -14 | N/A |
| 12/31/2021 | 0 | -14 | -13 | -13 | N/A |
| 9/30/2021 | N/A | -12 | -11 | -11 | N/A |
| 6/30/2021 | N/A | -10 | -10 | -10 | N/A |
| 3/31/2021 | N/A | -9 | -9 | -9 | N/A |
| 12/31/2020 | N/A | -7 | -6 | -6 | N/A |
| 9/30/2020 | N/A | -8 | -6 | -6 | N/A |
| 6/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2019 | N/A | -11 | -9 | -8 | N/A |
| 9/30/2019 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2019 | N/A | -10 | -7 | -7 | N/A |
| 3/31/2019 | N/A | -9 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -8 | -4 | -4 | N/A |
| 9/30/2018 | N/A | -7 | -4 | -4 | N/A |
| 6/30/2018 | N/A | -6 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -6 | N/A | -3 | N/A |
| 12/31/2017 | N/A | -5 | N/A | -3 | N/A |
| 9/30/2017 | N/A | -5 | N/A | -3 | N/A |
| 6/30/2017 | N/A | -3 | N/A | -2 | N/A |
| 3/31/2017 | N/A | -2 | N/A | -2 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -1 | N/A |
| 9/30/2016 | N/A | -2 | N/A | 0 | N/A |
| 6/30/2016 | N/A | -2 | N/A | 0 | N/A |
| 3/31/2016 | N/A | -3 | N/A | -1 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -2 | N/A |
| 9/30/2015 | N/A | -3 | N/A | -2 | N/A |
| 6/30/2015 | N/A | -3 | N/A | -2 | N/A |
| 3/31/2015 | N/A | -3 | N/A | -1 | N/A |
| 12/31/2014 | N/A | -2 | N/A | -1 | N/A |
| 9/30/2014 | N/A | -2 | N/A | -1 | N/A |
| 6/30/2014 | N/A | -1 | N/A | -1 | N/A |
| 3/31/2014 | N/A | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INM's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if INM's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if INM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if INM's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if INM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INM's Return on Equity is forecast to be high in 3 years time